Sign Up Today and Learn More About Neuralink Stock
Invest in or calculate the value of your shares in Neuralink or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Neuralink Stock (NEUR)
Neuralink is a neurotechnology company that focuses on developing brain-computer interfaces designed to treat neurological disorders.
About Neuralink Stock
Founded
2017
Headquarters
Fremont, CA, US
Total Funding
1.3B
Industries
Hardware, Software, Data and Analytics
Neuralink is a neurotechnology company developing implantable brain-computer interfaces (BCIs). The company's technology is designed to help individuals with neurological disorders restore mobility and communication abilities. Neuralink is also developing robotic surgical systems to perform the implantation procedure with high accuracy. By advancing implantable brain devices, Neuralink seeks to restore user independence and improve lives.
Neuralink Press Mentions
Stay in the know about the latest news on Neuralink
马斯克，操刀下一个万亿IPO深度
news • Jul 27, 2026
Neuralink实现意念操控电动轮椅
donews • Jul 25, 2026
Neuralink, la empresa más futurista de Elon Musk que en 2026 pasó de promesa científica a activo financiero
businessinsider • Jul 23, 2026
Los inversores valoran Neuralink de Elon Musk en 42.000 millones de dólares en mercados secundarios
businessinsider • Jul 23, 2026
Brain Interfaces Don’t Need Surgery to Be Transformative – and the Distinction Is Now a Strategic One
medcitynews • Jul 10, 2026
Investors in Neuralink
Discover investors in Neuralink stock and explore their portfolio companies
Neuralink Management
Leadership team at Neuralink
CEO
Jared Birchall
Co-Founder & Co-CEO
Elon Musk
Join now and verify your accreditation status to gain access to:
- Neuralink Current Valuation
- Neuralink Stock Price
- Neuralink Management
- Available deals in Neuralink and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Neuralink Cap Table and Funding History by Share Class and Liquidity Preferences
- Neuralink Revenue and Financials
- Neuralink Highlights
- Neuralink Business Model
- Neuralink Risk Factors
- Neuralink Research Report from SACRA Research
Neuralink Key Facts
- Clinical Expansion & Human Trial Success: Neuralink has successfully scaled its human clinical trials to 21 human patients as of mid-2026. Trial participants with severe motor impairment or ALS have reportedly demonstrated the ability to operate digital devices, execute creative work, and interact with software purely through thought. The company has broadened trials beyond the U.S. into international medical centers including the UK, Canada, and the UAE.
- Surgical Automation and Cost-Reduction Milestones: Neuralink introduced next-generation surgical robotics that lower electrode thread insertion time to 1.5 seconds per thread while reducing needle cartridge manufacturing costs by 95%. These technological advancements may reduce surgical friction, improve scalability, and establish a clear operational path toward automated, high-volume BCI procedures.
- Regulatory Fast-Tracking: Neuralink secured an FDA Breakthrough Device Designation for its vision-restoration device, Blindsight. The device works by stimulating the visual cortex to restore synthetic visual perception to individuals with lost vision or optic nerve damage. The designation provides direct regulatory support and prioritized FDA review.
- Hardware Stability & Biological Interface Risks: Clinical trials revealed an ongoing vulnerability where the brain’s natural microscopic movements cause the implant’s thin flexible threads to pull back from brain tissue, reducing the active electrode count. Although software updates restored partial signal processing, long-term scar tissue formation, biological encapsulation, and physical thread displacement could degrade device performance over time, potentially requiring complex revision surgeries or hardware redesigns.
- Emerging Competition from Less Invasive BCI Alternatives: Competitors are making rapid regulatory and clinical strides with lower-risk designs, threatening Neuralink's market capture. For instance, Precision Neuroscience received FDA clearance for its Layer 7 Cortical Interface, a surface-resting film array that avoids brain tissue penetration, while Synchron continues deploying endovascular interfaces.
- Regulatory Rigor and Extended Commercialization Timelines: Transitioning from early-stage investigational trials to full commercial Premarket Approval (PMA) presents steep regulatory hurdles. According to industry regulatory analysis, Class III medical device requirements, persistent FDA monitoring of adverse effects, cyber-security compliance, and trial attrition risks could delay broad commercial availability and scaling.
Trading Neuralink Stock
How to invest in Neuralink stock?
Accredited investors can buy pre-IPO stock in companies like Neuralink through EquityZen funds. These investments are made available by existing Neuralink shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Neuralink stock?
Shareholders can sell their Neuralink stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 56K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
